Effect of Symbiotic on Non-Alcoholic Fatty Liver Disease (NAFLD)

Effects of Symbiotic on inflammatory markers, liver function, lipid profile, sonographic findings and body composition in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013122811763N15

Enrollment

Registered

2014-01-02

Start date

2014-01-10

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NAFLD. Fatty (change of) liver

Interventions

Intervention 1: Daily oral consumption of Symbiotic supplement produced by Zist takhmir company with Familact commercial name contain 500 mg of seven Probiotic bacteria species and Fructooligosacchari

Treatment - Drugs

Daily oral consumption of Symbiotic supplement produced by Zist takhmir company with Familact commercial name contain 500 mg of seven Probiotic bacteria species and Fructooligosaccharides with below c

Daily Oral consumption of one tablet /day of placebo contain starch for two months and dietary recommendation about NAFLD to patients at the baseline

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:aged 18-60 years; confirmation of NAFLD with Ultrasonography and increased levels of Ast and Alt; desire to participate in the study. Exclusion criteria: organ transplantation; presence of pregnancy and lactation; suffering from Wilson disease; chronic liver diseases unless NAFLD; Diabetes Mellitus; Cancer; antibiotics therapy; Receiving Oral Contraceptive Pill (OCP); drugs such as corticosteroids, Amiodarone, Tamoxifen, Cyclins, Perhexiline, Methotrexate and Hydralazine; Receiving of vitamin-mineral and omega-3 Supplements during the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fatty liver grade. Timepoint: before and after the intervention. Method of measurement: Ultrasonography.;Alt_Ast. Timepoint: before and after the intervention. Method of measurement: by laboratory analysis (blood tests).;Lipid profiles. Timepoint: before and after the intervention. Method of measurement: by laboratory analysis (enzymatic).;Inflammatory markers. Timepoint: before and after the intervention. Method of measurement: Enzyme-Linked Immunosorbent Assay (ELISA).;Body composition. Timepoint: before and after the intervention. Method of measurement: Bioelectrical Impedance Assessment.	—

Measure

Time frame

Fatty liver grade. Timepoint: before and after the intervention. Method of measurement: Ultrasonography.;Alt_Ast. Timepoint: before and after the intervention. Method of measurement: by laboratory analysis (blood tests).;Lipid profiles. Timepoint: before and after the intervention. Method of measurement: by laboratory analysis (enzymatic).;Inflammatory markers. Timepoint: before and after the intervention. Method of measurement: Enzyme-Linked Immunosorbent Assay (ELISA).;Body composition. Timepoint: before and after the intervention. Method of measurement: Bioelectrical Impedance Assessment.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAtefe Asgharian

Isfahan University of Medical Sciences

Asgharian.Atefe@yahoo.com; Asgharian.Atefe@gmail.com; Asgharian@skums.ac.ir+98 31 1222 4458

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026